Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
Executive Summary
A patent term extension for Pfizer's Norvasc applies only to the besylate salt of amlodipine, Dr. Reddy's said in its motion to dismiss Pfizer's patent infringement suit
You may also be interested in...
Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor
FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway
Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor
FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway
Dr. Reddy’s Seeks Partner For Norvasc Salt, Says Pfizer Will Not Delay Launch
Dr. Reddy's is seeking a marketing partner to help promote amlodipine maleate upon FDA approval of the pending 505(b)(2) submission, CEO G.V. Prasad told investors during a June 2 conference call